Stock Taper
SCREENER COMPARE ANY 2 STOCKS
DTIL
PRECISION BIOSCIENCES, INC.
NASDAQ
$7.47
▲ UP 1.36% (0.10)

KEY STATISTICS

Market Cap$95.77 M
52w High$9.62
52w Low$3.53
Dividend Yield—
Frequency—
P/E-2.54
Volume124.17K
Shares Out.12.83M

COMPANY

LEADERSHIP

Michael Amoroso
CHIEF EXECUTIVE
Michael Amoroso

COMPENSATION 2026

Salary$650,875
Stock Awards$1,025,086
Incentive Plan Pay$0
All Other Comp.$62,212
Total$2,189,467

ABOUT

SECTOR
Healthcare
WENT PUBLIC
March 28, 2019
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
67

PRICE TARGET

Target High$20.00
Target Low$19.00
Target Median$19.50
Target Consensus$19.50

UPCOMING EARNINGS

DateNov 2, 2026
DayMonday
Rev. Est.$1.10M
NOV
2
MON

SPLIT RECORD

DATETYPERATIO
2024-02-14Reverse1:30

PRICE

$7.47 ▲ UP 1.36% (+$0.10)
OVERLAYS
$7.42$7.50$7.589:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM7.47

About Precision BioSciences, Inc.

https://www.precisionbiosciences.com ↗

Precision BioSciences, a Durham-based company, develops in vivo and ex vivo gene editing and CAR T therapies using its ARCUS platform to treat genetic disorders and cancers, with multiple candidates in clinical trials and strategic collaborations.

INDUSTRY

Biotechnology

A PRODUCT PRECISION BIOSCIENCES, INC. IS KNOWN FOR

PBGENE-DMD
PBGENE-DMD

Precision BioSciences' investigational in vivo gene editing therapy aims to treat Duchenne muscular dystrophy by correcting the dystrophin gene, with FDA clearance to begin Phase 1/2 clinical trials.

COMPETITORS

COMPETITOR
BEAM COMPARE
CRSP COMPARE
EDIT COMPARE
NTLA COMPARE
SRPT COMPARE

Revenue by Products

IconPRODUCTQ2-2025Q3-2025Q1-2026Q2-2026
License— — $6.8M $6.8M
Collaboration and License$100K $100K — —

ETFS HOLDING THIS STOCK

ETFS HOLDING
52
LISTED HERE
11
RANKED BY POSITION SIZE
VTS.AX
0.00% · 778.1K
XSU.TO
0.01% · 553.1K
FESM
0.01% · 118.7K
GSSC
0.02% · 35.2K
AVSC
0.01% · 28.7K
XRSU.L
0.01% · 21.8K
DFAS
0.00% · 20.8K
QQQS
0.53% · 16.1K
R2SC.L
0.00% · 12.1K
RSSL
0.01% · 11.4K
URTY
0.00% · 944

INSTITUTIONAL OWNERSHIP

SHARES OWNED
100.00%
HOLDERS
115
TOP 12 OF 115 · RANKED BY POSITION SIZE
Octagon Capital Advisors LP
2.2M sh · $12.3M
Abrdn Plc
2.2M sh · $12.27M
Empery Asset Management, LP
2.2M sh · $9.13B
Bleichroeder LP
1.7M sh · $9.14M
Oup Management Co., LLC
1.1M sh · $383.59K
Cowen Inc.
1.1M sh · $14.36M
Boothbay Fund Management, LLC
1.1M sh · $5.86M
Lynx1 Capital Management LP
1.0M sh · $5.76M
Driehaus Capital Management LLC
995.4K sh · $5.47M
Vanguard Group Inc
906.8K sh · $3.77M
Alyeska Investment Group, L.P.
798.0K sh · $3.32M
Aquilo Capital Management, LLC
726.1K sh · $3.46M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book2
Overall Score1

INSIDER TRADES

★
OFFICER: CHIELF ACCOUNTING OFFICER
Burris Mei Zhang Lu
— · 945 shares
2026-08-01
★
OFFICER: CHIEF SCIENTIFIC OFFICER
Gorsuch Cassandra Louise
— · 179.3K shares
2026-08-01
★
OFFICER: CHIEF FINANCIAL OFFICER
Tanna Naresh Haresh
— · —
2026-08-01
★
OFFICER: CHIELF ACCOUNTING OFFICER
Burris Mei Zhang Lu
— · 30.1K shares
2026-08-01

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
QTTB$12.06COMPARE
ALXO$2.16COMPARE
ALEC$2.52COMPARE
ARTV$11.15COMPARE
STRO$25.32COMPARE
RNA$14.17COMPARE
ABOS$3.21COMPARE
CNTB$2.21COMPARE